Drug Profile
BI 1291583
Alternative Names: BI-1291583Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antibronchitics
- Mechanism of Action Dipeptidyl peptidase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchiectasis
Most Recent Events
- 01 Mar 2024 Boehringer Ingelheim initiates a phase II Clairafly™ trial for Bronchiectasis (In adults, In the elderly) in US, Belgium and Germany (PO, Tablet) (NCT05865886) (EudraCT2022-502835-21-00)
- 07 Feb 2024 Boehringer Ingelheim completes a phase I pharmacokinetics trial (In volunteers) in Netherlands (PO) (NCT06166992, EudraCT2023-505683-11-00)
- 12 Dec 2023 Boehringer Ingelheim initiates a phase I pharmacokinetics trial (In volunteers) in Netherlands (PO) (NCT06166992, EudraCT2023-505683-11-00)